Company intelligence / Profile preview

InterCon

San Francisco, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

InterCon is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company leverages its expertise in immunology to create targeted treatments that address unmet medical needs in conditions such as rheumatoid arthritis and inflammatory bowel disease. InterCon's pipeline includes both small molecule inhibitors and monoclonal antibodies designed to modulate key inflammatory pathways. With a commitment to improving patient outcomes, InterCon is advancing several programs through various stages of clinical development.

Therapeutic areas: ImmunologyDermatologyGastroenterology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on InterCon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterCon.

Explore the full profile